

**Fintax International Growth Fund IC Limited**

**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

<b>Contents</b>	<b>Page</b>
General Information	3
Investment Manager's Report	4
Directors' Report	6
Independent Auditor's Report	7
Custodian's Report	9
Supplementary Information	10
Portfolio Statement	11
Statement of Financial Position	12
Statement of Comprehensive Income	13
Statement of Cash Flows	14
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	15
Notes to the Financial Statements	16

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**General Information**

**Address and Registered Office**

PO Box 255  
Trafalgar Court, Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 3QL

**Investment Manager**

Momentum Global Investment Management Limited  
The Rex Building  
62 Queen Street  
London  
EC4R 1EB  
United Kingdom

**Distribution Partner**

Fintax Consulting Group (Pty) Ltd  
No. 2 Seventh Avenue  
Parktown North  
2193, South Africa

**Manager**

Momentum Wealth International Limited  
La Plaiderie House  
La Plaiderie  
St Peter Port, Guernsey  
Channel Islands  
GY1 1WF

**Custodian**

Northern Trust (Guernsey) Limited  
PO Box 71  
Trafalgar Court  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 3DA

**Directors of the Incorporated Cell**

Robert Alastair Rhodes  
Roxanne Power  
Marie Curutchet  
Ferdinand van Heerden  
Kapil Joshi (appointed 23 February 2021)

**Administrator, Registrar & Secretary**

Northern Trust International Fund Administration  
Services (Guernsey) Limited  
PO Box 255  
Trafalgar Court  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 3QL

**Legal Advisor**

Carey Olsen  
Carey House  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 4BZ

**Independent Auditor**

Ernst & Young LLP  
PO Box 9  
Royal Chambers  
St Julian's Avenue  
St Peter Port, Guernsey  
Channel Islands  
GY1 4AF

# Fintax International Growth Fund IC Limited

## Annual Report and Audited Financial Statements for the year ended 30 June 2021

### Investment Manager's Report

#### June performance

Fintax International Growth Fund IC Limited (the "Fund") returned 1.2% in June and thus participated in most of the market upside. The reflation trade, which has favoured cyclical businesses like energy and material companies, paused in June as the spread of the COVID-19 delta variant pushed back the reopening of economies. Global technology stocks added 7% over the month, while more economically sensitive areas such as materials and financials fell by around 4%.

#### 12 month performance

Over the past 12 months, the key contributor to performance has been equity manager selection. Our top performing managers were our US deep value specialist, Lyrical, with an impressive return of 70.6% over the 12 month period; Chrysalis, who specialise in buying late stage private companies in the UK and Europe and have so far executed well on the strategy they set out at launch in 2018; and Sands within emerging markets, who specialise in identifying fast growing, sustainable companies.

#### Portfolio changes


We elected to roll our equity index put options to the end of September: if the S&P 500 index, which measures the prices of the largest US stocks, is lower at the end of September than it is today, these options will pay out, thus protecting the Fund to an extent. Option prices are cheap relative to their history and therefore we continue to hold options as an excellent hedge against potential bouts of volatility.

#### What are things worth?


With prices updated throughout the day, financial markets provide a convenient guide for investors trying to understand the value of their portfolios. However, they are not always a reliable guide. We saw the stock market's short-term failings in 2020 as COVID-19 brought company valuations down to levels that implied their futures were permanently impaired. Share prices in the longer term will almost certainly be closer to (and above) the recovered prices that we see today rather than the distressed levels of 2020.

Having conviction that times will change and prices will rebound requires other tools for discerning true, intrinsic worth, namely a focus on business fundamentals. This includes an assessment of a company's assets and their historical income/dividend generating potential, as well as the potential for future profit expansion. This approach has worked well for Lyrical, our US equity specialist, whose performance has rebounded over the past 12 months following a disappointing 2019/20:

**Underperformance between June 19-June 20**




**Subsequent outperformance between June 20-June 21**



Source: Bloomberg Finance L.P.

Lyrical made just five changes to their portfolio in 2020/21, but the stock market's assessment of the value of their holdings changed markedly, as these charts show.

A lot of the tools described above are backward-looking. We want to make sure the Fintax Funds don't exclusively own established, dividend-paying companies and therefore miss opportunities in innovative new businesses. The Fund's investments in Chrysalis, an investment trust which raises capital to buy late stage private companies, some of which are still loss-making as they pump resources into growing their customer base, has also been extremely rewarding over the past 12 months. Chrysalis own stakes in fast-growing companies including Klarna (online payments), Wise (fintech solutions), THG Plc (online shopping) and Embark (digital retirement solutions). The trust has sufficient scale and capital to attract and dictate terms of deals, and has executed on the strategy they set out at launch in 2018.



Source: Bloomberg Finance L.P.

We maintain a blend of managers in the Fund to ensure we are exposed to the asset classes we want; parts of the world that offer attractive returns; and also different types of companies, both new and established. Our active managers are able to look through short term dislocations in markets, to good returns in future.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Investment Manager's Report (continued)**

**Outlook**

The recent rise in COVID-19 cases around the world has been significant, prompting countries including the US, Japan, Australia and South Africa to introduce additional restrictions. However, with the latest data showing vaccinations are helping to reduce hospitalisations and deaths, we maintain our view that vaccine programmes offer a credible path out of the pandemic for economies. Thus, with the economic boom still upon us, we think equities and other economically sensitive assets offer good prospective returns from here. Notwithstanding this positive outlook for risk assets, we continue to own protective assets in the form of the aforementioned put options, as well as precious metals, to protect against bouts of volatility.

Parts of South Africa have witnessed social unrest following the 15-month imprisonment of former President Jacob Zuma. This unrest has resulted in loss of life, damage to infrastructure and extensive looting of businesses. Besides concerns over food shortages and supply chain disruptions, it is deeply concerning that many of these businesses will take months to reopen their doors (if they decide to at all) which will put further upward pressure on the unemployment rate. This clearly comes at a very difficult time for South Africa, as the country tries to rebuild in the wake of the pandemic, but we trust that South Africans will show the same resilience as they have done in the past and that conditions have improved materially by the time you read this.

# **Fintax International Growth Fund IC Limited**

## **Annual Report and Audited Financial Statements for the year ended 30 June 2021**

### **Directors' Report**

The Directors present their annual report together with the audited financial statements of Fintax International Growth Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2021.

#### **Principal activities**

The Cell with company number 47771 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 16.

#### **Going Concern**

The Directors have made an assessment of going concern including consideration of the ongoing impact of the COVID-19 global pandemic on the Cell. Refer to note 2 for the detailed disclosure.

#### **Directors**

The Directors of the Cell during the year and at the date of this report are set out on page 3.

#### **Directors' interests**

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

#### **Directors' responsibilities**

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Incorporated Cell for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 1987. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell has complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.

The annual report together with the audited financial statements of the Incorporated Cell is published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

#### **Independent auditors**

Ernst & Young LLP have indicated their willingness to continue in office. The reappointment of Ernst & Young LLP will be proposed within the next written resolution to deal with annual business.



**Marie Curutchet**  
**Director**  
3 November 2021



**Robert Rhodes**  
**Director**

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Independent Auditor's Report to the Members of Fintax International Growth Fund IC Limited**

**Opinion**

We have audited the financial statements of Fintax International Growth Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2021 which comprise the Statement of Comprehensive Income, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, the Statement of Financial Position, the Statement of Cash Flows and the related notes 1 to 17, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- ▶ give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2021 and of its profit for the year then ended;
- ▶ have been properly prepared in accordance with International Financial Reporting Standards;
- ▶ have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and Protection of Investors (Bailiwick of Guernsey) Law, 1987;

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for a period to 31 December 2022 from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

**Other information**

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- ▶ proper accounting records have not been kept by the Incorporated Cell; or
- ▶ the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- ▶ we have not received all the information and explanations we require for our audit.

**Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Independent Auditor's Report to the Members of Fintax International Growth Fund IC Limited (continued)**

**Auditor's responsibilities for the audit of the financial statements (continued)**

*Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud*

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- ▶ We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and Protection of Investors (Bailiwick of Guernsey) Law, 1987);
- ▶ We understood how the Incorporated Cell is complying with those frameworks by making enquiries of management and those responsible for compliance matters and corroborated this by reviewing minutes of meetings of the Board of Directors and correspondence between the Incorporated Cell and the Guernsey Financial Services Commission. We gained an understanding of the Board's approach to governance, demonstrated by its review of compliance reports, the investment manager's reports and internal control processes;
- ▶ We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how fraud might occur by considering the risk of management override and by identifying the recognition of realised gains and losses on investments at year-end (cut-off) as a fraud risk. We considered the controls the Incorporated Cell has established to address the risk identified by the directors or that otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor those controls. We also considered the existence of any stakeholder influences which may cause management to seek to manipulate the financial performance and did not note any;
- ▶ Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of compliance reports; review of correspondence with the Guernsey Financial Services Commission; making inquiries of those charged with governance; and performance of journal entry testing based on our risk assessment and understanding of the business, with a focus on non-standard journals and those relating to areas with an identified associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**Use of our report**

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.02(3) of the Authorised Collective Investment Schemes (Class B) Rules, 2013. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:  
  
4753914588A54C3...

**Ernst & Young LLP**  
**Guernsey, Channel Islands**

Date: **November 9, 2021**

**Notes:**

1. The maintenance and integrity of the Momentum Mutual Fund ICC Limited web site is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the web site.
2. Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Custodian's Report to the Members of Fintax International Growth Fund IC Limited (the "Incorporated Cell" or "Cell")**

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2021 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules 2013.

The image shows two handwritten signatures in black ink. The signature on the left is 'Nadia Senary' and the signature on the right is 'Brandon'. Both are written in a cursive, flowing style.

**For and on behalf of**  
**Northern Trust (Guernsey) Limited**  
3 November 2021

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Supplementary Information**

	<b>30.06.21</b>	<b>30.06.20</b>
<b>1. NUMBER OF SHARES OUTSTANDING</b>		
Class A	7,245,049	8,265,286
<b>2. NET ASSET VALUE PER SHARE - USD</b>		
Class A	1.89	1.41
<b>3. HIGHEST/LOWEST PRICE - USD*</b>		
Class A	1.90 / 1.41	1.64 / 1.09
<b>4. NUMBER OF SHARES SUBSCRIBED</b>		
Class A	128,685	110,036
<b>5. NUMBER OF SHARES REDEEMED</b>		
Class A	1,148,922	895,329

\*The highest/lowest price is based on prices from prior year-end to current year-end, being the 30.06.2021. The NAV on the 30.06.2021 was specifically calculated for financial reporting purposes and therefore may differ slightly from the most recent published price at that time.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Portfolio Statement**

	Holdings	Fair Value <u>USD</u>	% of Net Assets
<b>Financial assets at fair value through profit or loss</b>			
<b>Equities: 0.00% (2020: 5.06%)</b>			
<b>Collective Investment Schemes: 98.20% (2020: 92.04%)</b>			
<b>Commodity Funds</b>			
iShares Physical Gold ETF	20,594	708,640	5.19
<b>Total Commodity Funds</b>		<b>708,640</b>	<b>5.19</b>
<b>Equity Funds</b>			
Alma Hotchkis & Wiley Global Value Fund Class I	6,798	876,330	6.41
Amundi Jpx-Nikkei 400 UCITS ETF	2,478	445,941	3.26
Artisan Global Value Fund	57,857	1,608,425	11.77
Conventum Lyrical Fund Class S	3,365	671,549	4.91
Dimensional Emerging Markets Value Fund USD Acc	12,105	303,237	2.22
Maple-Brown Abbott Global Fund	119	172	-
Morgan Stanley Global Sustain Fund Class F	110,294	1,870,458	13.69
Morgan Stanley Investment Funds - Global Brands Fund	9	1,877	0.01
PGIM Jennison Global Equity Opportunities Fund	2,684	846,507	6.19
Prusik Asian Equity Income Fund Class U	2,598	567,572	4.15
Sands Capital Funds - Sands Capital Global Growth Fund	29,534	1,717,993	12.57
Sands Capital Funds - Sands Emerging Markets Growth Fund	24,020	568,553	4.16
TB Evenlode Global Income Fund Class F	240,963	494,491	3.62
Veritas Funds - Global Focus Fund	32,305	1,729,618	12.66
<b>Total Equity Funds</b>		<b>11,702,723</b>	<b>85.62</b>
<b>Fixed Income Funds</b>			
Institutional Cash Series - Institutional US Dollar Ultra Short Bond Fund	5,817	632,996	4.63
<b>Total Fixed Income Funds</b>		<b>632,996</b>	<b>4.63</b>
<b>Investment Trusts</b>			
Merian Chrysalis Investment Company Limited	111,000	377,219	2.76
<b>Total Investment Trusts</b>		<b>377,219</b>	<b>2.76</b>
<b>Property Funds</b>			
Third Avenue Real Estate Value Fund		88	-
<b>Total Property Funds</b>		<b>88</b>	<b>-</b>
<b>Total Collective Investment Schemes</b>		<b>13,421,666</b>	<b>98.20</b>
<b>Options: 0.17% (2020: 0.13%)</b>			
S&P 500 Index Put 4280 30/09/2021	2	23,240	0.17
<b>Total Options</b>		<b>23,240</b>	<b>0.17</b>
<b>Financial assets at fair value through profit or loss</b>		<b>13,444,906</b>	<b>98.37</b>
<b>Other Net Assets: 1.63% (2020: USD322,585; 2.77%)</b>		<b>219,914</b>	<b>1.63</b>
<b>Net Assets Attributable To Holders Of Participating Redeemable Shares</b>		<b>13,664,820</b>	<b>100.00</b>

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Statement of Financial Position**

	Notes	30.06.21 <u>USD</u>	30.06.20 <u>USD</u>
<b>ASSETS</b>			
<b>CURRENT ASSETS</b>			
Financial assets at fair value through profit or loss	6	13,444,906	11,337,145
Cash and cash equivalents	7	242,378	318,070
Fair value of derivative financial instruments	6 & 8	21,020	18,023
Other receivables	9	284	252
		<u>13,708,588</u>	<u>11,673,490</u>
<b>Total assets</b>		<u><b>13,708,588</b></u>	<u><b>11,673,490</b></u>
<b>LIABILITIES</b>			
<b>CURRENT LIABILITIES</b>			
Securities purchased payable		24,485	-
Other payables	10	19,281	13,758
Liabilities (excluding net assets attributable to holders of participating redeemable shares)		43,766	13,758
Net assets attributable to holders of participating redeemable shares	3 & 12	<u>13,664,820</u>	<u>11,659,730</u>
<b>Total liabilities</b>		<u><b>13,708,586</b></u>	<u><b>11,673,488</b></u>
<b>SHAREHOLDERS' EQUITY</b>			
Management Shares	11	2	2
<b>Total equity</b>		<u><b>2</b></u>	<u><b>2</b></u>
<b>Total equity and liabilities</b>		<u><b>13,708,588</b></u>	<u><b>11,673,490</b></u>
Net asset value per participating redeemable share	12	1.89	1.41

The notes 1 to 17 on pages 16 to 26 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 3 November 2021 and signed on its behalf by:



**Marie Curutchet**  
**Director**



**Robert Rhodes**  
**Director**

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Statement of Comprehensive Income**

	Notes	Year ended 30.06.21 <u>USD</u>	Year ended 30.06.20 <u>USD</u>
<b>INCOME</b>			
Net realised gains on financial assets at fair value through profit or loss	6	487,644	843,433
Change in unrealised gains/(losses) on financial assets at fair value through profit or loss	6	3,141,877	(1,764,648)
Net gains/(losses) on financial assets at fair value through profit or loss		3,629,521	(921,215)
Dividend income		71,086	111,132
Net (losses)/gains on derivatives		(61,126)	33,752
Other foreign exchange (losses)/gains		(18,686)	15,258
Other income		210	7,479
<b>Total net income/(loss)</b>		<b>3,621,005</b>	<b>(753,594)</b>
<b>OPERATING EXPENSES</b>			
Audit fee		(12,530)	(6,799)
Custodian fee	14	(10,389)	(10,521)
Investment Management fee	14	(31,070)	(31,546)
Manager and Administration fee	14	(29,802)	(25,421)
Deposit interest		(57)	(278)
Sundry expenses		(5,333)	(3,125)
<b>Total operating expenses</b>		<b>(89,181)</b>	<b>(77,690)</b>
<b>Net profit/(loss) before tax</b>		<b>3,531,824</b>	<b>(831,284)</b>
Withholding tax		(4,059)	(7,407)
<b>Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations</b>		<b>3,527,765</b>	<b>(838,691)</b>

All items in the above statement derive from continuing operations. There is no difference between the increase/(decrease) in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 17 on pages 16 to 26 form part of these financial statements.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Statement of Cash Flows**

	<b>Year ended</b> <b>30.06.21</b> <u><b>USD</b></u>	<b>Year ended</b> <b>30.06.20</b> <u><b>USD</b></u>
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations	3,527,765	(838,691)
<b>ADJUSTMENT FOR:</b>		
Net realised gains on financial assets at fair value through profit or loss	(487,644)	(843,433)
Net unrealised (gains)/losses on financial assets at fair value through profit or loss	(3,141,877)	1,764,648
Net settlement on derivatives and other foreign exchange	15,689	(23,647)
Dividend income	(71,086)	(111,132)
Withholding tax	4,059	7,407
<b>Operating loss before working capital changes</b>	<b>(153,094)</b>	<b>(44,848)</b>
Net (increase)/decrease in other receivables	(32)	1,124
Net increase in other payables	5,523	310
Purchase of financial assets at fair value through profit or loss	(5,122,866)	(9,789,258)
Sale of financial assets at fair value through profit or loss	6,669,111	11,022,215
Dividend received	67,027	103,725
<b>Net cash generated from operating activities</b>	<b>1,465,669</b>	<b>1,293,268</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Cash received from issuance of participating redeemable shares	240,987	155,400
Cash paid on redemption of participating redeemable shares	(1,763,662)	(1,305,110)
<b>Net cash used in financing activities</b>	<b>(1,522,675)</b>	<b>(1,149,710)</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(57,006)</b>	<b>143,558</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>318,070</b>	<b>159,254</b>
Effect of foreign exchange rate on cash	(18,686)	15,258
<b>Cash and cash equivalents at the end of the year</b>	<b>242,378</b>	<b>318,070</b>

The notes 1 to 17 on pages 16 to 26 form part of these financial statements.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**  
**Statements of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares**

	Notes	Year ended 30.06.21 <u>USD</u>	Year ended 30.06.20 <u>USD</u>
Net assets attributable to holders of participating redeemable shares at the beginning of the year		11,659,730	13,648,131
Proceeds from issuance of participating redeemable shares	11	240,987	155,400
Payments on redemption of participating redeemable shares	11	(1,763,662)	(1,305,110)
Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations		3,527,765	(838,691)
<b>Net assets attributable to holders of participating redeemable shares at the end of the year</b>	<b>12</b>	<b><u>13,664,820</u></b>	<b><u>11,659,730</u></b>

The notes 1 to 17 on pages 16 to 26 form part of these financial statements.

# Fintax International Growth Fund IC Limited

## Annual Report and Audited Financial Statements for the year ended 30 June 2021

### Notes to the Financial Statements

#### 1. General Information

The Fintax International Growth Fund IC Limited (the "Incorporated Cell" or "Cell"), with company number 47771, is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company").

The Cell's objective is capital appreciation. The Cell is suitable for investors with a time horizon of greater than 7 years.

The Cell intends to achieve its investment objectives by investing primarily in other collective investment schemes, whose underlying portfolios provide exposure to a diversified portfolio of equity investments across a wide range of markets and sectors globally, and across a broad range of currencies over time. A small and restricted exposure to underlying portfolios which invest in asset classes such as cash, money market instruments, fixed income, property, alternatives strategies and commodities, as well as asset allocation portfolios that provide exposure to a combination of these asset classes, may also be included in the Cell. The Cell may also invest in transferable securities which are classes of investments that are negotiable on a capital market such as (but not limited to) shares in companies or bond investments. Exposure to any asset class may also be achieved by investing in regulated insurance products.

The Cell may use futures, options and swap contracts and enter into forward foreign exchange transactions for the purposes of efficient portfolio management and risk reduction or to protect or enhance investment performance. The Investment Manager intends to primarily use options, the cost of which are fixed at the point of purchase. The Cell may invest in the units of collective investment schemes which are also managed by the Investment Manager or an associate of the Investment Manager. Neither the Manager nor any such associated company shall be liable to account to investors for any profit, charges or remuneration made or received by the Manager or any such associated company and the Manager's fee shall not be abated thereby.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager") with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager").

On 1 March 2021, amendments were made to the Supplemental Prospectus of the Cell:

- Sections (A) Investment Objective and Section (B) Investment Policy were amended as described above.
- Sections (B) Investment Policy – the Cell's exposure to asset classes was amended to:
  - o 80% - 100% Equities
  - o 0% - 20% Cash and/or Money Markets
  - o 0% – 20% Fixed Income
  - o 0% – 20% Alternative Strategies
  - o 0% – 20% Alternative Strategies
  - o 0% – 20% Commodities
  - o 0% – 20% Equity market options (gross nominal exposure)
- Sections (D) Derivatives Risk – the Options disclosure has been changed to include that the Cell's exposure to options is limited, as specified within the Investment Policy. The price of options varies over time depending on market conditions and the term of the option.
- Sections (D) Derivatives Risk has been updated to state that the use of derivatives may lead to large changes in the value of the Cell and includes the potential for large financial loss if improperly managed. The value of a derivative typically depends on the value of an underlying asset. The value of the derivative may not be 100% correlated with the value of the underlying asset and therefore a change in the value of the asset may not be matched by a proportionate corresponding change in the value of the derivative.

The financial statements were authorised for issue by the Board of Directors on 3 November 2021.

#### 2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

##### 2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards (IFRS). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

##### Going concern

The COVID-19 pandemic and the resultant uncertain economic environment and financial market volatility caused by it continues to create uncertainty in the operating environment of the Cell. All service providers have continued to operate effectively throughout the relevant COVID-19 local government restrictions. No concerns regarding liquidity, valuations or COVID-19 service provider issues have been identified that cause the Board to have any concern regarding the ongoing operation of the Cell or that require any changes to the Financial Statements of the Cell.

Notwithstanding the challenges arising from the impact of the COVID-19 virus, the Cell continues to operate, administer and price the funds in accordance with regulatory requirements and in accordance with relevant accounting standards. The Cell will continue to monitor fund liquidity and market volatility to ensure funds are managed in the best interests of shareholders.

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2022 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.

# Fintax International Growth Fund IC Limited

## Annual Report and Audited Financial Statements for the year ended 30 June 2021

### Notes to the Financial Statements (continued)

#### 2. Summary of significant accounting policies (continued)

##### 2.2 Adoption of new and revised standards

*Standards, amendments and interpretations effective during the year*

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2020:

- (a) Definition of a Business (Amendments to IFRS 3)
- (b) Amendments to References to the Conceptual Framework in IFRS Standards
- (c) Definition of Material (Amendments to IAS 1 and IAS 8)
- (d) Interest Rate Benchmark Reform - phase 1 (Amendments to IFRS 9, IAS 39 and IFRS 7)

Periods beginning on or after 1 June 2020:

- (e) COVID-19-Related Rent Concessions (Amendment to IFRS 16)

In March 2021 the International Accounting Standards Board issued COVID-19-Related Rent Concessions beyond 30 June 2021, which extended the availability of the practical expedient by one year.

The adoption of these standards has not had a material impact on the financial statements of the Incorporated Cell.

*Standards, amendments and interpretations in issue not yet effective*

A number of new standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2021 and have not been early adopted in preparing these financial statements. These include:

- (a) Interest Rate Benchmark Reform - Phase 2 (Amendments to IFRS 9, IAS 39 and IFRS 7) - Effective from 1 January 2021

Amendments to assist in the application of IFRS standards when changes are made to contractual cash flows or hedging relationships due to the IBOR reforms.

- (b) IAS 16 - Property, Plant and Equipment - Effective from 1 January 2022

Amendments prohibiting a company from deducting from the cost of property, plant and equipment amounts received from selling items produced.

- (c) IAS 1 - Presentation of Financial Statements (Amendments) - Effective from 1 January 2023

Amendments regarding classification of liabilities and disclosure of accounting policies.

- (d) IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - Effective from 1 January 2023

Amendments regarding the definition of accounting estimates.

- (e) IFRS 17 – Insurance Contracts. Effective from 1 January 2023

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

##### 2.3 Foreign currency translation

- (a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

- (b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.

##### 2.4 Financial assets and financial liabilities at fair value through profit or loss

- (a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities, and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

- (b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

- (c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

# **Fintax International Growth Fund IC Limited**

## **Annual Report and Audited Financial Statements for the year ended 30 June 2021**

### **Notes to the Financial Statements (continued)**

#### **2. Summary of significant accounting policies (continued)**

##### **2.4 Financial assets and financial liabilities at fair value through profit or loss**

###### **(d) Fair value estimation**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.

##### **2.5 Offsetting financial instruments**

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

##### **2.6 Forward currency contracts**

Forward foreign currency contracts are treated as derivative contracts and as such, are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

##### **2.7 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

##### **2.8 Other financial instruments**

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

##### **2.9 Share capital**

The Incorporated Cell has an authorised share capital of 100 management shares of USD1.00 each and an unlimited number of no par value participating

###### **(a) Management shares**

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 2 Management Shares.

###### **(b) Participating redeemable shares**

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

##### **2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations**

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.

##### **2.11 Capital risk management**

The fair value of the Cell's financial assets and financial liabilities approximate to its carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objectives when managing capital is to safeguard their ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

##### **2.12 Interest and dividend income**

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**2. Summary of significant accounting policies (continued)**

**2.13 Expenses**

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

**2.14 Custodian bank charges**

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

**2.15 Taxation**

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2020: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

**3. Financial risk management**

**3.1 Strategy in using financial instruments**

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year. The fair value of derivative financial instruments as at 30 June 2021 is disclosed under note 8 of these financial statements.

The Cell's policies allow it to use derivative financial instruments to both moderate and create certain risk exposure.

**3.2 Market price risk**

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in collective investment schemes. Through its investment in traded securities and instruments the Cell is subject to market movements in the equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposure to varying product categories, hence concentration of risk is minimised. At the year-end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

	2021		2020	
	Fair Value	% of net assets	Fair Value	% of net assets
	<u>USD</u>		<u>USD</u>	
Collective Investment Schemes	13,421,666	98.20	10,782,705	92.04
Equities	-	-	589,640	5.06
Options	23,240	0.17	14,800	0.13
	<b>13,444,906</b>	<b>98.37</b>	<b>11,387,145</b>	<b>97.23</b>

The Cell's market price risk is affected by three main components: changes in actual market prices, interest rate and foreign currency movements. Interest rate and foreign currency exchange rate movements are covered in notes 3.3 and 3.5, respectively. If the market indexes increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2021	2020
	Change in fair value	
	<u>USD</u>	<u>USD</u>
Collective Investment Schemes	1,342,167	1,073,271
Equities	-	58,964
Options	2,324	1,480
	<b>1,344,491</b>	<b>1,133,715</b>

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**3. Financial risk management (continued)**

**3.3 Interest rate risk**

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risks. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

<b>As at 30 June</b>	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Net financial assets on which no interest is paid	13,378,182	11,341,660
Net floating rate financial assets	242,378	318,070

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

<b>As at 30 June</b>	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Movement in net floating rate financial assets	1,212	1,590

**3.4 Cash flow risk**

The Cell holds a limited amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

**3.5 Currency risk**

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments denominated in currencies other than its functional currency, US Dollar, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Investments made via Collective Investment Funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

<b>As at 30 June</b>	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
EUR exposure	16,608	29,164
GBP exposure	3,784,700	3,194,152
SGD exposure	12,560	12,102

In accordance with the Cell's policies, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk. Such contracts are used on a regular basis. The contracts which are outstanding at the year-end are disclosed in note 8.

Should the Cell's functional currency have strengthened or weakened by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

<b>As at 30 June</b>	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
EUR exposure	830	1,458
GBP exposure	189,235	159,708
SGD exposure	628	605

# Fintax International Growth Fund IC Limited

## Annual Report and Audited Financial Statements for the year ended 30 June 2021

### Notes to the Financial Statements (continued)

#### 3. Financial risk management (continued)

##### 3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by the Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with its cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.

##### 3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short-term liquidity requirements, however to date the Cell has not entered into such arrangements.

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is insignificant.

	Less than 1 month	Between 1 and 12 months	2021 Total	2020 Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	13,421,666	23,240	13,444,906	11,337,145
Cash and cash equivalents	242,378	-	242,378	318,070
Fair value of derivative financial instruments	-	21,020	21,020	-
Other receivables	282	-	282	250
Securities purchased payable	(24,485)	-	(24,485)	-
Fair value of derivative financial instruments	-	-	-	18,023
Other payables	(19,281)	-	(19,281)	(13,758)
Net assets attributable to participating redeemable shareholders	(13,664,820)	-	(13,664,820)	(11,659,730)
<b>Net liquidity position</b>	<b>(44,260)</b>	<b>44,260</b>	<b>-</b>	<b>-</b>

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

##### 3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The Cell's overall strategy remains unchanged.

The Cell has no externally imposed capital requirements.

##### 3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and fair values of the financial assets and liabilities.

#### 4. Critical accounting estimates and judgments

The fair value of investments is considered to be the quoted, active market prices, or prices as supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**5. Portfolio analysis**

The Cell's portfolio is organised by focusing on the type of security held, and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2. and the following main geographical areas:

	<b>2021</b>	<b>2020</b>
	<b>USD</b>	<b>USD</b>
Europe	10,679,498	8,853,924
Channel Islands	377,219	658,566
United Kingdom	2,364,949	1,809,855
United States	23,240	14,800
	<b>13,444,906</b>	<b>11,337,145</b>

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.

**6. Financial assets at fair value through profit or loss**

	<b>2021</b>	<b>2020</b>
	<b>USD</b>	<b>USD</b>
<b>Financial assets at fair value through profit or loss:</b>		
Collective Investment Schemes	13,421,666	10,732,705
Equity Funds	-	589,640
Options	23,240	14,800
<b>Total financial assets at fair value through profit or loss</b>	<b>13,444,906</b>	<b>11,337,145</b>

	<b>2021</b>	<b>2020</b>
	<b>USD</b>	<b>USD</b>
<b>Movement on financial assets at fair value through profit or loss</b>		
Fair value of financial assets at the beginning of the year	11,337,145	13,491,317
Purchases of financial assets	5,122,866	9,789,258
Sales of financial assets	(6,644,626)	(11,022,215)
Realised gains on sales of financial assets	487,644	843,433
Movement in unrealised gains/(losses) on revaluation of financial assets	3,141,877	(1,764,648)
Fair value of financial assets at the end of the year	<b>13,444,906</b>	<b>11,337,145</b>
Comprising:		
Cost at the end of the year	9,804,036	10,838,152
Unrealised gains at the end of the year	3,640,870	498,993
	<b>13,444,906</b>	<b>11,337,145</b>

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 – inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**6. Financial assets at fair value through profit or loss (continued)**

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2021 and 30 June 2020:

**30 June 2021**

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>
<b>Financial assets at fair value through profit or loss</b>				
Collective Investment Schemes	13,421,666	-	-	13,421,666
Options	23,240	-	-	23,240
Fair value of derivative financial instruments	-	21,020	-	21,020
	<u>13,444,906</u>	<u>21,020</u>	<u>-</u>	<u>13,465,926</u>

**30 June 2020**

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>
<b>Financial assets at fair value through profit or loss</b>				
Collective Investment Schemes	10,732,705	-	-	10,732,705
Equities	589,640	-	-	589,640
Options	14,800	-	-	14,800
Fair value of derivative financial instruments	-	18,023	-	18,023
	<u>11,337,145</u>	<u>18,023</u>	<u>-</u>	<u>11,355,168</u>

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

**7. Cash and cash equivalents**

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	<b>2021</b>	<b>2020</b>
	<b>USD</b>	<b>USD</b>
Cash at bank	242,378	318,070
	<u>242,378</u>	<u>318,070</u>

**8. Derivative Financial Instruments**

Forward foreign exchange contracts designated as at fair value through profit or loss:

<b>30 June 2021</b>	<b>Amount</b>	<b>Maturity Date</b>	<b>Contracted rate</b>	<b>Closing rate</b>	<b>Contract value</b>	<b>Market value</b>	<b>Financial assets / (liabilities)</b>
	<b>CCY</b>				<b>USD</b>	<b>USD</b>	<b>USD</b>
Outstanding contract to sell EUR	EUR 215,000	18/08/2021	0.8166	0.8432	(263,279)	(254,969)	8,310
Outstanding contract to sell GBP	GBP 370,000	18/08/2021	0.7063	0.7239	(523,847)	(511,137)	12,710
							<u>21,020</u>
<b>Fair value of derivative financial instruments - asset</b>							<u>21,020</u>

<b>30 June 2020</b>	<b>Amount</b>	<b>Maturity Date</b>	<b>Contracted rate</b>	<b>Closing rate</b>	<b>Contract value</b>	<b>Market value</b>	<b>Financial assets / (liabilities)</b>
	<b>CCY</b>				<b>USD</b>	<b>USD</b>	<b>USD</b>
Outstanding contract to sell EUR	EUR 400,000	15/07/2020	0.9174	0.8904	436,032	449,260	13,228
Outstanding contract to buy EUR	EUR 200,000	15/07/2020	0.9240	0.8904	216,455	224,630	8,175
Outstanding contract to sell GBP	GBP 525,000	15/07/2020	0.8019	0.8093	654,702	648,690	(6,012)
Outstanding contract to buy GBP	GBP 175,000	15/07/2020	0.8193	0.8093	213,598	216,230	2,632
							<u>18,023</u>
<b>Fair value of derivative financial instruments - asset</b>							<u>18,023</u>

In accordance with the Cell's investment objectives, the Cell may enter into forward foreign exchange contracts to hedge foreign currency movements they may be exposed to through its investment portfolio. As there is no assurance that these hedges will be effective in achieving the offsetting of changes in cash flows attributable to currency risk on these investments it is the policy of the Cell not to apply hedge accounting.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**9. Other receivables**

	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Prepayments	282	250
Management shares receivable	2	2
	<b><u>284</u></b>	<b><u>252</u></b>

**10. Other payables**

	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Management fee payable	3,006	2,039
Custodian fee payable	723	699
Investment management fee payable	3,056	2,548
Audit fee payable	9,837	7,221
Sundry expense payable	2,659	1,251
	<b><u>19,281</u></b>	<b><u>13,758</u></b>

**11. Share capital**

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no-par value participating redeemable shares.

<b>Management Shares in Issue</b>	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Management shares	2	2

	<b>Year ended</b>	<b>Year ended</b>
	<b>30.06.21</b>	<b>30.06.20</b>
<b>Participating Redeemable Shares in Issue</b>		
Balance at the beginning of the year	8,265,286	9,050,579
Issue of participating redeemable shares	128,685	110,036
Redemption of participating redeemable shares	(1,148,922)	(895,329)
<b>Balance at the end of the year</b>	<b><u>7,245,049</u></b>	<b><u>8,265,286</u></b>

	<b>Year ended</b>	<b>Year ended</b>
	<b>30.06.21</b>	<b>30.06.20</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
<b>Participating Redeemable Share Capital Account</b>		
Balance at the beginning of the year	6,717,934	7,867,644
Issue of participating redeemable shares	240,987	155,400
Redemption of participating redeemable shares	(1,763,662)	(1,305,110)
<b>Balance at the end of the year</b>	<b><u>5,195,259</u></b>	<b><u>6,717,934</u></b>

**12. Net asset value per participating redeemable share**

	<b>NAV per share</b>	<b>Net assets attributable</b>	<b>Shares in issue</b>	<b>NAV per share</b>	<b>Net assets attributable</b>	<b>Shares in issue</b>
<b>As at 30 June</b>	<b>2021</b>	<b>2021</b>	<b>2021</b>	<b>2020</b>	<b>2020</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>		<b><u>USD</u></b>	<b><u>USD</u></b>	
	1.89	13,664,820	7,245,049	1.41	11,659,730	8,265,286

**13. Dividends payable to participating redeemable shareholders**

No dividends were paid during the year (2020: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**14. Related-party transactions**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager is entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD22,000 or currency equivalent.

<u>Fee - % of NAV per</u>	<u>Cell NAV</u>
0.20%	Up to USD30m
0.15%	Over USD30m

**14.1 Management and Administration fee**

Management and Administration fee charged during the year and accrued at year-end:

	<u>2021</u>	<u>2020</u>
	<u>USD</u>	<u>USD</u>
Charged during the year	29,802	25,421
Accrued at year-end	<u>3,006</u>	<u>2,039</u>

Management fee rebate received during the year and accrued at year-end:

	<u>2021</u>	<u>2020</u>
	<u>USD</u>	<u>USD</u>
Received during the year	210	(1,222)
Accrued at year-end	<u>-</u>	<u>-</u>

**14.2 Investment Management fee**

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell. The Investment Manager is entitled to receive a fee (the "Investment Management fee"), chargeable at a rate of 0.25% of the Cell's NAV per annum, which will accrue as at each Valuation Point, based on the current valuation of the Cell, payable monthly in arrears.

Investment Management fee charged during the year and accrued at year end:

	<u>2021</u>	<u>2020</u>
	<u>USD</u>	<u>USD</u>
Charged during the year	31,070	31,546
Accrued at year-end	<u>3,056</u>	<u>2,548</u>

**14.3 Custodian fee**

The Cell has engaged the services of Northern Trust (Guernsey) Limited to provide custodian services. The Custodian is entitled to the payment of a fee (the "Custody fee") chargeable on a sliding scale in respect of all Share Classes, as follows, subject to a minimum of USD8,000 per annum.

<u>Fee% of NAV per annum</u>	<u>Cell NAV</u>
0.05%	Up to USD30m
0.04%	From USD30m to USD60m
0.03%	From USD60m to USD100m
0.02%	Over USD100m

Custodian fee charged during the year and accrued at year-end:

	<u>2021</u>	<u>2020</u>
	<u>USD</u>	<u>USD</u>
Charged during the year	10,389	10,521
Accrued at year-end	<u>723</u>	<u>699</u>

**Fintax International Growth Fund IC Limited**  
**Annual Report and Audited Financial Statements for the year ended 30 June 2021**

**Notes to the Financial Statements (continued)**

**14. Related-party transactions (continued)**

**14.4 Distribution Partner fee**

The Cell has appointed Fintax Consulting Group (Pty) Ltd as distribution partner to promote and market the Cell. The Distribution Partner is entitled to receive a fee of up to 0.5% of the NAV of the Cell per annum (the "Distribution Partner fee"). The Distribution Partner fee will accrue as at each Valuation Point, based on the current valuation of the Cell and is payable monthly in arrears. The Distribution Partner will also be entitled to be paid any expenses and disbursements reasonably incurred in performance of its duties.

Since inception, and until further notice, the Distribution Partner has waived their fees.

**14.5 Board of Director's remuneration**

The Directors' fees in respect of the Cell shall not exceed USD20,000 (or currency equivalent) in any twelve-month period. In addition, the Directors shall be entitled to be repaid for all reasonable out-of-pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the Cellular assets of other Cells of the Company or assets of the Company itself.

The Directors waived their right to a fee in 2021 (2020: Nil).

**15. Ultimate controlling party**

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

**16. Reconciliation of published valuation to financial statements**

	<b>2021</b>	<b>2020</b>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Net assets per financial statements	13,664,820	11,659,730
Adjustment:		
Adjustment in value of assets at financial assets at fair value through profit and loss	34,750	(46,744)
Adjustment in value of derivative financial instruments	(286)	(14,518)
Net assets per published valuation	<u>13,699,284</u>	<u>11,598,468</u>
	<b><u>USD</u></b>	<b><u>USD</u></b>
Shares in issue per published NAV as at 30 June	7,245,049	8,265,286
Shares in issue per Financial Statements	7,245,049	8,265,286
NAV per share per published valuation	<u>1.89</u>	<u>1.40</u>
NAV per share per financial statements	<u>1.89</u>	<u>1.41</u>

**17. Subsequent events**

These financial statements were approved for issuance by the Board on 3 November 2021. Subsequent events have been evaluated until this date.

No significant events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.